LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
NRC
National Research Corporation
There isn't enough reported data to score NRC yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NRC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Weak |
NRC's cash flow is currently strong, and its revenue and profitability are stable, but its balance sheet is weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NRC PE Valuation
NRC has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NRC Forward outlook
There aren't enough analyst estimates for NRC to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus NRC down 39%.
NRC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | $0.69 | -39% |
| Q2 2025 | $0.75 | -38% |
| Q1 2025 | $1.02 | -18% |
| Q4 2024 | $1.04 | -17% |
| Q3 2024 | $1.13 | -2.6% |
| Q2 2024 | $1.21 | +3.4% |
| Q1 2024 | $1.24 | +2.5% |
| Q4 2023 | $1.25 | -1.6% |
NRC's earnings per share have fallen from their peak: $0.69 over the past year, against $1.47 in late 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NRC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NRC on profitability, with a higher operating margin.
NRC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $38.4M | +11% |
| Q2 2026 | $35.4M | +4% |
| Q1 2026 | $34.8M | +3.7% |
| Q4 2025 | $35.2M | -4.6% |
| Q3 2025 | $34.6M | -3.4% |
| Q2 2025 | $34M | -2.8% |
| Q1 2025 | $33.6M | -5% |
| Q4 2024 | $36.9M | -2.9% |
NRC's revenue has held roughly level: $38M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +0.8 points |
| Q2 2026 | -9.2% | -14 points |
| Q1 2026 | 16% | -9.6 points |
| Q4 2025 | 13% | -13 points |
| Q3 2025 | 22% | +0.1 points |
| Q2 2025 | 4.7% | -21 points |
| Q1 2025 | 26% | +0.8 points |
| Q4 2024 | 26% | -4.8 points |
NRC's operating margin was 23% last quarter, up 0.8 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over NRC on cash flow, with more consistent year-over-year improvement.
NRC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $7M | -31% |
| Q2 2026 | $62K | +$4.2M |
| Q1 2026 | $5.3M | +46% |
| Q4 2025 | $6.1M | +213% |
| Q3 2025 | $10.2M | +30% |
| Q2 2025 | -$4.1M | -374% |
| Q1 2025 | $3.7M | -54% |
| Q4 2024 | $1.9M | -76% |
NRC still generates free cash flow, though less than at its 2020 peak: $18M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NRC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -122K shares |
| 1 year | -1.1% | -243K shares |
| 3 years | -11% | -2.8M shares |
| 5 years | -15% | -3.8M shares |
| Available history | -13% | -3.1M shares |
NRC has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $16M |
| Q2 2026 | $7.6M |
| Q1 2026 | $1.9M |
| Q4 2025 | $1,000 |
| Q3 2025 | $9.3M |
| Q2 2025 | $6M |
| Q1 2025 | $4.9M |
| Q4 2024 | $7.4M |
NRC spent $26M buying back its own shares over the past year, down 7.3% from the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over NRC on leverage, with a lower net debt burden relative to earnings.
NRC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.1x | High |
| Q2 2026 | 3.7x | Elevated |
| Q1 2026 | 2.6x | Moderate |
| Q4 2025 | 2.4x | Moderate |
| Q3 2020 | 0.1x | Very low |
| Q2 2020 | 0.4x | Very low |
| Q1 2020 | 0.4x | Very low |
| Q4 2019 | 0.3x | Very low |
NRC's net debt is about 4.1 years of its operating earnings (EBITDA), up from less than a year a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NRC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.6 | Overbought |
| Stochastic | 87.0 | Overbought |
NRC's weekly RSI is 73 (overbought) and its Stochastic is 87 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NRC PE vs Healthcare Sector
| Metric | NRC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NRC has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
NRC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.3 | 19% above |
| 20 week MA | $21.7 | 23% above |
| 50 week MA | $19.3 | 38% above |
| 100 week MA | $17.0 | 56% above |
| 200 week MA | $26.4 | 0.9% above |
NRC has climbed back above all five of its weekly moving averages, and it's now 0.9% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
NRC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.6 | $44.4 | -33% |
| 2021 | $44.4 | $41.5 | -6.5% |
| 2022 | $41.5 | $37.3 | -10% |
| 2023 | $37.3 | $39.6 | +6.1% |
| 2024 | $39.6 | $17.4 | -56% |
| 2025 | $17.4 | $18.7 | +7.1% |
| 2026 YTD | $18.7 | $26.6 | +43% |
NRC has the edge over LLY on returns for 2026, with the stronger performance.